This report was recently updated on May 10 2024 with the latest and most recent
market numbers
Global Exon Skipping Drugs Market Size, Trends & Analysis - Forecasts to 2029 By Therapeutic Indication (Duchenne Muscular Dystrophy (DMD) and Other Genetic Disorders), By Exon Target (Exon 51 Skipping, Exon 53 Skipping, Exon 45 Skipping, and Other Exon Targets), By Phase of Development (Preclinical, Clinical (Phase I, II, III), and Approved), and By Region (North America, Asia Pacific, Central & South America, Europe, and Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and End User Analysis
The global exon skipping drugs market is analyzed to grow at a CAGR of 40.8% during the forecast period from 2024 to 2029. Exon skipping therapies work by targeting specific genetic mutations that cause these disorders, allowing cells to produce functional proteins despite the mutation.
The market is driven by factors such as the growing prevalence of genetic disorders and advancements in gene editing technologies. The rising occurrence of genetic conditions like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) is fueling the demand for exon skipping medications. These drugs present a promising treatment avenue by identifying specific genetic mutations and reinstating protein production, thus tackling the root cause of these ailments. Constant advancements in biotechnology and gene editing technologies have notably bolstered the progress of exon skipping medications. Breakthroughs in methods such as CRISPR-Cas9 and antisense oligonucleotides (ASOs) have enhanced the accuracy and effectiveness of exon skipping therapies, hastening their research and development. The opportunity exists to broaden the therapeutic uses beyond rare genetic disorders. With deeper insights into exon skipping mechanisms, researchers can explore its potential in treating a more comprehensive array of diseases, including specific cancers and other genetic conditions.
One significant restraint in the exon skipping drugs market is the high cost associated with treatment. These therapies often involve complex manufacturing processes and specialized delivery methods, contributing to their expensive price tags.
Based on exon target, the market is segmented into exon 51 skipping, exon 53 skipping, exon 45 skipping, and other exon targets. The exon 51 skipping segment is expected to hold the largest share of the market during the forecast period. Diseases such as Duchenne muscular dystrophy (DMD) often involve mutations in specific exons, and exon 51 is frequently implicated in such cases. As DMD is one of the most common and well-known genetic disorders targeted by exon skipping therapies, the demand for treatments focusing on exon 51 skipping is notably high.
The exon 53 skipping segment is projected to grow fastest during the forecast period. Advancements in biotechnology have facilitated the development of exon skipping drugs targeting exon 53, leading to increased interest and investment in this area. Promising clinical trial results have propelled exon 53 skipping to become the fastest-growing segment in the market.
Based on therapeutic indication, the market is segmented into Duchenne muscular dystrophy (DMD) and other genetic disorders. Duchenne muscular dystrophy (DMD) segment is expected to hold the largest share of the market during the forecast period. DMD is one of the most prevalent genetic disorders targeted by exon skipping therapies, driving substantial demand for treatments within this segment. Moreover, ongoing research efforts and clinical trials specifically focus on developing exon skipping drugs for DMD, further solidifying its market dominance.
Based on phase of development, the market is segmented into preclinical, clinical (Phase I, II, III), and approved. The clinical segment is expected to hold the largest share of the market during the forecast period. It encompasses a wide range of ongoing trials across Phase I, II, and III, reflecting the extensive research and development efforts in exon skipping therapies.
The approved segment is projected to grow fastest during the forecast period. This growth in the approved segment signifies the increasing success rate of exon skipping treatments and the translation of promising trial results into market-ready therapies. As more drugs transition from clinical trials to approved status, the approved segment is expected to witness significant expansion, reflecting the growing confidence in exon skipping drugs among regulators and healthcare providers.
North America is analyzed to be the largest region in the global exon skipping drugs market during the forecast period. This can be attributed to its robust research and development infrastructure, high healthcare expenditures, a large patient population with genetic disorders, and favorable regulatory policies facilitating the approval and commercialization of exon skipping therapies in the region.
Asia Pacific is analyzed to be the fastest-growing region in the global exon skipping drugs market during the forecast period. There has been a noticeable increase in awareness and diagnosis rates of genetic conditions in the Asia Pacific region. This heightened awareness is leading to earlier detection and intervention, thereby driving the demand for innovative treatments like exon skipping drugs. Additionally, the region is experiencing significant growth in healthcare infrastructure and expenditure, facilitating improved access to advanced genetic therapies. The expanding pharmaceutical industry in the Asia Pacific is increasingly focusing on rare diseases, including those targeted by exon-skipping drugs, contributing to the market's growth. Moreover, rising investments in biotechnology and gene therapy research are fueling the development of novel treatments for genetic disorders, further propelling the growth of the exon skipping drugs market in the region.
Sarepta Therapeutics, NS Pharma, Avidity Bioscience, PTC Therapeutics, Wave Life Sciences, Santhera Pharmaceuticals, Dyne Therapeutics, Pfizer, and Regenxbio, among others, are some of the key players operating in the global market.
Please note: This is not an exhaustive list of companies profiled in the report.
In January 2024, Sarepta Therapeutics announced positive data from part B of MOMENTUM, a Phase 2 Study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51.
1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS
1.1 Strategic Opportunity & Attractiveness Analysis
1.1.1 Hot Revenue Pockets
1.1.2 Market Attractiveness Score
1.1.3 Revenue Impacting Opportunity
1.1.4 High Growing Region/Country
1.1.5 Competitor Analysis
1.1.6 Consumer Analysis
1.2 Global Market Estimates' View
1.3 Strategic Insights across Business Functions
1.3.1 For Chief Executive Officers
1.3.2 For Chief Marketing Officers
1.3.3 For Chief Strategy Officers
1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into
2 TECHNOLOGICAL TRENDS
2.1 Technological Adoption Rate
2.2 Current Trend Impact Analysis
2.3 Future Trend Impact Analysis
3 GLOBAL EXON SKIPPING DRUGS MARKET OUTLOOK
3.1 Market Pyramid Analysis
3.1.1 Introduction
3.1.2 Adjacent Market Opportunities
3.1.3 Ancillary Market Opportunities
3.2 Demand Side Analysis
3.2.1 Market Drivers: Impact Analysis
3.2.2 Market Restraints: Impact Analysis
3.2.3 Market Opportunities: Impact Analysis
3.2.4 Market Challenges: Impact Analysis
3.3 Supply Side Analysis
3.3.1 Porter’s Five Forces Analysis
3.3.1.1 Threat of New Entrants
3.3.1.2 Threat of New Substitutes
3.3.1.3 Bargaining Power of Suppliers
3.3.1.4 Bargaining Power of Buyers
3.3.1.5 Intensity of Competitive Rivalry
3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
3.3.2.1 Political Landscape
3.3.2.2 Economic Landscape
3.3.2.3 Social Landscape
3.3.2.4 Technology Landscape
3.3.3 Value Chain Analysis
3.3.4 Trend Analysis
3.3.5 Gap Analysis
3.3.6 Cost Analysis
4 GLOBAL EXON SKIPPING DRUGS MARKET, BY THERAPEUTIC INDICATION
4.1 Introduction
4.2 Exon Skipping Drugs Market: Therapeutic Indication Scope Key Takeaways
4.3 Revenue Growth Analysis, 2023 & 2029
4.4 Duchenne Muscular Dystrophy (DMD)
4.4.1 Duchenne Muscular Dystrophy (DMD) Market Estimates and Forecast, 2021-2029 (USD Million)
4.5 Other Genetic Disorders
4.5.1 Other Genetic Disorders Market Estimates and Forecast, 2021-2029 (USD Million)
5 GLOBAL EXON SKIPPING DRUGS MARKET, BY EXON TARGET
5.1 Introduction
5.2 Exon Skipping Drugs Market: Exon Target Scope Key Takeaways
5.3 Revenue Growth Analysis, 2023 & 2029
5.4 Exon 51 Skipping
5.4.1 Exon 51 Skipping Market Estimates and Forecast, 2021-2029 (USD Million)
5.5 Exon 53 Skipping
5.5.1 Exon 53 Skipping Market Estimates and Forecast, 2021-2029 (USD Million)
5.6 Exon 45 Skipping
5.6.1 Exon 45 Skipping Market Estimates and Forecast, 2021-2029 (USD Million)
5.7 Other Exon Targets
5.7.1 Other Exon Targets Market Estimates and Forecast, 2021-2029 (USD Million)
6 GLOBAL EXON SKIPPING DRUGS MARKET, BY PHASE OF DEVELOPMENT
6.1 Introduction
6.2 Exon Skipping Drugs Market: Pharse of Development Scope Key Takeaways
6.3 Revenue Growth Analysis, 2023 & 2029
6.4 Preclinical
6.4.1 Preclinical Market Estimates and Forecast, 2021-2029 (USD Million)
6.5 Clinical (Phase I, II, III)
6.5.1 Clinical (Phase I, II, III) Market Estimates and Forecast, 2021-2029 (USD Million)
6.6 Approved
6.6.1 Approved Market Estimates and Forecast, 2021-2029 (USD Million)
7 GLOBAL EXON SKIPPING DRUGS MARKET, BY REGION
7.1 Introduction
7.2 North America Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.1 By Therapeutic Indication
7.2.2 By Exon Target
7.2.3 By Phase of Development
7.2.4 By Country
7.2.4.1 U.S. Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.1.1 By Therapeutic Indication
7.2.4.1.2 By Exon Target
7.2.4.1.3 By Phase of Development
7.2.4.2 Canada Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.2.1 By Therapeutic Indication
7.2.4.2.2 By Exon Target
7.2.4.2.3 By Phase of Development
7.2.4.3 Mexico Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.2.4.3.1 By Therapeutic Indication
7.2.4.3.2 By Exon Target
7.2.4.3.3 By Phase of Development
7.3 Europe Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.1 By Therapeutic Indication
7.3.2 By Exon Target
7.3.3 By Phase of Development
7.3.4 By Country
7.3.4.1 Germany Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.1.1 By Therapeutic Indication
7.3.4.1.2 By Exon Target
7.3.4.1.3 By Phase of Development
7.3.4.2 U.K. Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.2.1 By Therapeutic Indication
7.3.4.2.2 By Exon Target
7.3.4.2.3 By Phase of Development
7.3.4.3 France Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.3.1 By Therapeutic Indication
7.3.4.3.2 By Exon Target
7.3.4.3.3 By Phase of Development
7.3.4.4 Italy Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.4.1 By Therapeutic Indication
7.3.4.4.2 By Exon Target
7.2.4.4.3 By Phase of Development
7.3.4.5 Spain Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.5.1 By Therapeutic Indication
7.3.4.5.2 By Exon Target
7.2.4.5.3 By Phase of Development
7.3.4.6 Netherlands Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.6.1 By Therapeutic Indication
7.3.4.6.2 By Exon Target
7.2.4.6.3 By Phase of Development
7.3.4.7 Rest of Europe Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.3.4.7.1 By Therapeutic Indication
7.3.4.7.2 By Exon Target
7.2.4.7.3 By Phase of Development
7.4 Asia Pacific Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.1 By Therapeutic Indication
7.4.2 By Exon Target
7.4.3 By Phase of Development
7.4.4 By Country
7.4.4.1 China Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.1.1 By Therapeutic Indication
7.4.4.1.2 By Exon Target
7.4.4.1.3 By Phase of Development
7.4.4.2 Japan Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.2.1 By Therapeutic Indication
7.4.4.2.2 By Exon Target
7.4.4.2.3 By Phase of Development
7.4.4.3 India Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.3.1 By Therapeutic Indication
7.4.4.3.2 By Exon Target
7.4.4.3.3 By Phase of Development
7.4.4.4 South Korea Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.4.1 By Therapeutic Indication
7.4.4.4.2 By Exon Target
7.4.4.4.3 By Phase of Development
7.4.4.5 Singapore Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.5.1 By Therapeutic Indication
7.4.4.5.2 By Exon Target
7.4.4.5.3 By Phase of Development
7.4.4.6 Malaysia Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.6.1 By Therapeutic Indication
7.4.4.6.2 By Exon Target
7.4.4.6.3 By Phase of Development
7.4.4.7 Thailand Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.7.1 By Therapeutic Indication
7.4.4.7.2 By Exon Target
7.4.4.7.3 By Phase of Development
7.4.4.8 Indonesia Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.8.1 By Therapeutic Indication
7.4.4.8.2 By Exon Target
7.4.4.8.3 By Phase of Development
7.4.4.9 Vietnam Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.9.1 By Therapeutic Indication
7.4.4.9.2 By Exon Target
7.4.4.9.3 By Phase of Development
7.4.4.10 Taiwan Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.10.1 By Therapeutic Indication
7.4.4.10.2 By Exon Target
7.4.4.10.3 By Phase of Development
7.4.4.11 Rest of Asia Pacific Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.4.4.11.1 By Therapeutic Indication
7.4.4.11.2 By Exon Target
7.4.4.11.3 By Phase of Development
7.5 Middle East and Africa Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.1 By Therapeutic Indication
7.5.2 By Exon Target
7.5.3 By Phase of Development
7.5.4 By Country
7.5.4.1 Saudi Arabia Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.1.1 By Therapeutic Indication
7.5.4.1.2 By Exon Target
7.5.4.1.3 By Phase of Development
7.5.4.2 U.A.E. Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.2.1 By Therapeutic Indication
7.5.4.2.2 By Exon Target
7.5.4.2.3 By Phase of Development
7.5.4.3 Israel Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.3.1 By Therapeutic Indication
7.5.4.3.2 By Exon Target
7.5.4.3.3 By Phase of Development
7.5.4.4 South Africa Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.4.1 By Therapeutic Indication
7.5.4.4.2 By Exon Target
7.5.4.4.3 By Phase of Development
7.5.4.5 Rest of Middle East and Africa Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.5.4.5.1 By Therapeutic Indication
7.5.4.5.2 By Exon Target
7.5.4.5.2 By Phase of Development
7.6 Central & South America Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.1 By Therapeutic Indication
7.6.2 By Exon Target
7.6.3 By Phase of Development
7.6.4 By Country
7.6.4.1 Brazil Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.1.1 By Therapeutic Indication
7.6.4.1.2 By Exon Target
7.6.4.1.3 By Phase of Development
7.6.4.2 Argentina Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.2.1 By Therapeutic Indication
7.6.4.2.2 By Exon Target
7.6.4.2.3 By Phase of Development
7.6.4.3 Chile Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.3.1 By Therapeutic Indication
7.6.4.3.2 By Exon Target
7.6.4.3.3 By Phase of Development
7.6.4.4 Rest of Central & South America Exon Skipping Drugs Market Estimates and Forecast, 2021-2029 (USD Million)
7.6.4.4.1 By Therapeutic Indication
7.6.4.4.2 By Exon Target
7.6.4.4.3 By Phase of Development
8 COMPETITIVE LANDCAPE
8.1 Company Market Share Analysis
8.2 Four Quadrant Positioning Matrix
8.2.1 Market Leaders
8.2.2 Market Visionaries
8.2.3 Market Challengers
8.2.4 Niche Market Players
8.3 Vendor Landscape
8.3.1 North America
8.3.2 Europe
8.3.3 Asia Pacific
8.3.4 Rest of the World
8.4 Company Profiles
8.4.1 Sarepta Therapeutics
8.4.1.1 Business Description & Financial Analysis
8.4.1.2 SWOT Analysis
8.4.1.3 Products & Services Offered
8.4.1.4 Strategic Alliances between Business Partners
8.4.2 NS Pharma
8.4.2.1 Business Description & Financial Analysis
8.4.2.2 SWOT Analysis
8.4.2.3 Products & Services Offered
8.4.2.4 Strategic Alliances between Business Partners
8.4.3 Avidity Bioscience
8.4.3.1 Business Description & Financial Analysis
8.4.3.2 SWOT Analysis
8.4.3.3 Products & Services Offered
8.4.3.4 Strategic Alliances between Business Partners
8.4.4 PTC Therapeutics
8.4.4.1 Business Description & Financial Analysis
8.4.4.2 SWOT Analysis
8.4.4.3 Products & Services Offered
8.4.4.4 Strategic Alliances between Business Partners
8.4.5 Wave Life Sciences
8.4.5.1 Business Description & Financial Analysis
8.4.5.2 SWOT Analysis
8.4.5.3 Products & Services Offered
8.4.5.4 Strategic Alliances between Business Partners
8.4.6 SANTHERA PHARMACEUTICALS
8.4.6.1 Business Description & Financial Analysis
8.4.6.2 SWOT Analysis
8.4.6.3 Products & Services Offered
8.4.6.4 Strategic Alliances between Business Partners
8.4.7 Dyne Therapeutics
8.4.7.1 Business Description & Financial Analysis
8.4.7.2 SWOT Analysis
8.4.7.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.8 Pfizer
8.4.8.1 Business Description & Financial Analysis
8.4.8.2 SWOT Analysis
8.4.8.3 Products & Services Offered
8.4.8.4 Strategic Alliances between Business Partners
8.4.9 REGENXBIO
8.4.9.1 Business Description & Financial Analysis
8.4.9.2 SWOT Analysis
8.4.9.3 Products & Services Offered
8.4.9.4 Strategic Alliances between Business Partners
8.4.10 Other Companies
8.4.10.1 Business Description & Financial Analysis
8.4.10.2 SWOT Analysis
8.4.10.3 Products & Services Offered
8.4.10.4 Strategic Alliances between Business Partners
9 RESEARCH METHODOLOGY
9.1 Market Introduction
9.1.1 Market Definition
9.1.2 Market Scope & Segmentation
9.2 Information Procurement
9.2.1 Secondary Research
9.2.1.1 Purchased Databases
9.2.1.2 GMEs Internal Data Repository
9.2.1.3 Secondary Resources & Third Party Perspectives
9.2.1.4 Company Information Sources
9.2.2 Primary Research
9.2.2.1 Various Types of Respondents for Primary Interviews
9.2.2.2 Number of Interviews Conducted throughout the Research Process
9.2.2.3 Primary Stakeholders
9.2.2.4 Discussion Guide for Primary Participants
9.2.3 Expert Panels
9.2.3.1 Expert Panels Across 30+ Industry
9.2.4 Paid Local Experts
9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region
9.3 Market Estimation
9.3.1 Top-Down Approach
9.3.1.1 Macro-Economic Indicators Considered
9.3.1.2 Micro-Economic Indicators Considered
9.3.2 Bottom Up Approach
9.3.2.1 Company Share Analysis Approach
9.3.2.2 Estimation of Potential Product Sales
9.4 Data Triangulation
9.4.1 Data Collection
9.4.2 Time Series, Cross Sectional & Panel Data Analysis
9.4.3 Cluster Analysis
9.5 Analysis and Output
9.5.1 Inhouse AI Based Real Time Analytics Tool
9.5.2 Output From Desk & Primary Research
9.6 Research Assumptions & Limitations
9.7.1 Research Assumptions
9.7.2 Research Limitations
LIST OF TABLES
1 Global Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
2 Duchenne Muscular Dystrophy (DMD) Market, By Region, 2021-2029 (USD Million)
3 Other Genetic Disorders Market, By Region, 2021-2029 (USD Million)
4 Global Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
5 Exon 51 Skipping Market, By Region, 2021-2029 (USD Million)
6 Exon 53 Skipping Market, By Region, 2021-2029 (USD Million)
7 Exon 45 Skipping Market, By Region, 2021-2029 (USD Million)
8 Other Exon Targets Market, By Region, 2021-2029 (USD Million)
9 Global Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
10 Preclinical Market, By Region, 2021-2029 (USD Million)
11 CLINICAL (PHASE I, II, III) Market, By Region, 2021-2029 (USD Million)
12 APPROVED Market, By Region, 2021-2029 (USD Million)
13 Regional Analysis, 2021-2029 (USD Million)
14 North America Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
15 North America Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
16 North America Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
17 North America Exon Skipping Drugs Market, By Country, 2021-2029 (USD Million)
18 U.S Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
19 U.S Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
20 U.S Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
21 Canada Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
22 Canada Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
23 Canada Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
24 Mexico Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
25 Mexico Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
26 Mexico Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
27 Europe Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
28 Europe Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
29 Europe Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
30 Europe Exon Skipping Drugs Market, By COUNTRY, 2021-2029 (USD Million)
31 Germany Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
32 Germany Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
33 Germany Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
34 UK Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
35 UK Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
36 UK Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
37 France Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
38 France Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
39 France Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
40 Italy Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
41 Italy Exon Skipping Drugs Market, By T End Use Type, 2021-2029 (USD Million)
42 Italy Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
43 Spain Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
44 Spain Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
45 Spain Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
46 Rest Of Europe Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
47 Rest Of Europe Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
48 Rest of Europe Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
49 Asia Pacific Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
50 Asia Pacific Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
51 Asia Pacific Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
52 Asia Pacific Exon Skipping Drugs Market, By Country, 2021-2029 (USD Million)
53 China Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
54 China Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
55 China Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
56 India Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
57 India Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
58 India Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
59 Japan Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
60 Japan Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
61 Japan Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
62 South Korea Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
63 South Korea Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
64 South Korea Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
65 Malaysia Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
66 Malaysia Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
67 Malaysia Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
68 Vietnam Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
69 Vietnam Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
70 Vietnam Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
71 Rest of Asia Pacific Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
72 Rest of Asia Pacific Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
73 Rest of Asia Pacific Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
74 Middle East and Africa Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
75 Middle East and Africa Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
76 Middle East and Africa Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
77 Middle East and Africa Exon Skipping Drugs Market, By Country, 2021-2029 (USD Million)
78 Saudi Arabia Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
79 Saudi Arabia Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
80 Saudi Arabia Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
81 UAE Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
82 UAE Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
83 UAE Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
84 Rest of Middle East and Africa Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
85 Rest of Middle East and Africa Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
86 Rest of Middle East and Africa Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
87 Central & South America Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
88 Central & South America Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
89 Central & South America Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
90 Central & South America Exon Skipping Drugs Market, By Country, 2021-2029 (USD Million)
91 Brazil Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
92 Brazil Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
93 Brazil Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
94 Argentina Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
95 Argentina Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
96 Argentina Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
97 Rest of Central & South America Exon Skipping Drugs Market, By Therapeutic Indication, 2021-2029 (USD Million)
98 Rest of Central & South America Exon Skipping Drugs Market, By Exon Target, 2021-2029 (USD Million)
99 Rest of Central & South America Exon Skipping Drugs Market, By Phase of Development, 2021-2029 (USD Million)
100 Sarepta Therapeutics: Products & Services Offering
101 NS Pharma: Products & Services Offering
102 Avidity Bioscience: Products & Services Offering
103 PTC Therapeutics: Products & Services Offering
104 Wave Life Sciences: Products & Services Offering
105 SANTHERA PHARMACEUTICALS: Products & Services Offering
106 Dyne Therapeutics: Products & Services Offering
107 Pfizer: Products & Services Offering
108 REGENXBIO: Products & Services Offering
109 Other Companies: Products & Services Offering
LIST OF FIGURES
1 Global Exon Skipping Drugs Market Overview
2 Global Exon Skipping Drugs Market Value From 2021-2029 (USD Million)
3 Global Exon Skipping Drugs Market Share, By Therapeutic Indication (2023)
4 Global Exon Skipping Drugs Market Share, By Exon Target (2023)
5 Global Exon Skipping Drugs Market Share, By Phase of Development (2023)
6 Global Exon Skipping Drugs Market, By Region (Asia Pacific Market)
7 Technological Trends In Global Exon Skipping Drugs Market
8 Four Quadrant Competitor Positioning Matrix
9 Impact Of Macro & Micro Indicators On The Market
10 Impact Of Key Drivers On The Global Exon Skipping Drugs Market
11 Impact Of Challenges On The Global Exon Skipping Drugs Market
12 Porter’s Five Forces Analysis
13 Global Exon Skipping Drugs Market: By Therapeutic Indication Scope Key Takeaways
14 Global Exon Skipping Drugs Market, By Therapeutic Indication Segment: Revenue Growth Analysis
15 Duchenne Muscular Dystrophy (DMD) Market, By Region, 2021-2029 (USD Million)
16 Other Genetic Disorders Market, By Region, 2021-2029 (USD Million)
17 Global Exon Skipping Drugs Market: By Exon Target Scope Key Takeaways
18 Global Exon Skipping Drugs Market, By Exon Target Segment: Revenue Growth Analysis
19 Exon 51 Skipping Market, By Region, 2021-2029 (USD Million)
20 Exon 53 Skipping Market, By Region, 2021-2029 (USD Million)
21 Exon 45 Skipping Market, By Region, 2021-2029 (USD Million)
22 Other Exon Targets Skipping Market, By Region, 2021-2029 (USD Million)
23 Global Exon Skipping Drugs Market: By Phase of Development Scope Key Takeaways
24 Global Exon Skipping Drugs Market, By Phase of Development Segment: Revenue Growth Analysis
25 Preclinical Market, By Region, 2021-2029 (USD Million)
26 Clinical (Phase I, II, III) Market, By Region, 2021-2029 (USD Million)
27 Approved Market, By Region, 2021-2029 (USD Million)
28 Regional Segment: Revenue Growth Analysis
29 Global Exon Skipping Drugs Market: Regional Analysis
30 North America Exon Skipping Drugs Market Overview
31 North America Exon Skipping Drugs Market, By Therapeutic Indication
32 North America Exon Skipping Drugs Market, By Exon Target
33 North America Exon Skipping Drugs Market, By Phase of Development
34 North America Exon Skipping Drugs Market, By Country
35 U.S. Exon Skipping Drugs Market, By Therapeutic Indication
36 U.S. Exon Skipping Drugs Market, By Exon Target
37 U.S. Exon Skipping Drugs Market, By Phase of Development
38 Canada Exon Skipping Drugs Market, By Therapeutic Indication
39 Canada Exon Skipping Drugs Market, By Exon Target
40 Canada Exon Skipping Drugs Market, By Phase of Development
41 Mexico Exon Skipping Drugs Market, By Therapeutic Indication
42 Mexico Exon Skipping Drugs Market, By Exon Target
43 Mexico Exon Skipping Drugs Market, By Phase of Development
44 Four Quadrant Positioning Matrix
45 Company Market Share Analysis
46 Sarepta Therapeutics: Company Snapshot
47 Sarepta Therapeutics: SWOT Analysis
48 Sarepta Therapeutics: Geographic Presence
49 NS Pharma: Company Snapshot
50 NS Pharma: SWOT Analysis
51 NS Pharma: Geographic Presence
52 Avidity Bioscience: Company Snapshot
53 Avidity Bioscience: SWOT Analysis
54 Avidity Bioscience: Geographic Presence
55 PTC Therapeutics: Company Snapshot
56 PTC Therapeutics: Swot Analysis
57 PTC Therapeutics: Geographic Presence
58 Wave Life Sciences: Company Snapshot
59 Wave Life Sciences: SWOT Analysis
60 Wave Life Sciences: Geographic Presence
61 SANTHERA PHARMACEUTICALS: Company Snapshot
62 SANTHERA PHARMACEUTICALS: SWOT Analysis
63 SANTHERA PHARMACEUTICALS: Geographic Presence
64 Dyne Therapeutics: Company Snapshot
65 Dyne Therapeutics: SWOT Analysis
66 Dyne Therapeutics: Geographic Presence
67 Pfizer: Company Snapshot
68 Pfizer: SWOT Analysis
69 Pfizer: Geographic Presence
70 REGENXBIO.: Company Snapshot
71 REGENXBIO.: SWOT Analysis
72 REGENXBIO.: Geographic Presence
73 Other Companies: Company Snapshot
74 Other Companies: SWOT Analysis
75 Other Companies: Geographic Presence
The Global Exon Skipping Drugs Market has been studied from the year 2019 till 2029. However, the CAGR provided in the report is from the year 2024 to 2029. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Exon Skipping Drugs Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
